BSE Live
Oct 17, 15:44Prev. Close
1240.05
Open Price
1240.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1256.00 (2)
NSE Live
Oct 17, 15:50Prev. Close
1240.20
Open Price
1245.00
Bid Price (Qty.)
1255.90 (123)
Offer Price (Qty.)
0.00 (0)
Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 64.22 | 260.95 | 157.37 | 97.85 | 131.84 | |
Diluted EPS (Rs.) | 64.22 | 260.46 | 157.03 | 97.85 | 131.46 | |
Cash EPS (Rs.) | 76.60 | 318.80 | 212.24 | 146.48 | 181.57 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 346.00 | 1,453.29 | 1,228.94 | 1,101.94 | 1,020.66 | |
Book Value [InclRevalReserve]/Share (Rs.) | 346.00 | 1,453.29 | 1,228.94 | 1,101.94 | 1,020.66 | |
Dividend / Share(Rs.) | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 | |
Revenue from Operations/Share (Rs.) | 277.16 | 1,168.09 | 1,018.16 | 865.70 | 802.23 | |
PBDIT/Share (Rs.) | 100.54 | 407.00 | 288.48 | 184.86 | 236.65 | |
PBIT/Share (Rs.) | 88.08 | 348.51 | 233.07 | 135.93 | 186.47 | |
PBT/Share (Rs.) | 86.76 | 347.20 | 232.05 | 133.64 | 183.67 | |
Net Profit/Share (Rs.) | 64.14 | 260.31 | 156.83 | 97.55 | 131.39 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 36.27 | 34.84 | 28.33 | 21.35 | 29.49 | |
PBIT Margin (%) | 31.77 | 29.83 | 22.89 | 15.70 | 23.24 | |
PBT Margin (%) | 31.30 | 29.72 | 22.79 | 15.43 | 22.89 | |
Net Profit Margin (%) | 23.14 | 22.28 | 15.40 | 11.26 | 16.37 | |
Return on Networth / Equity (%) | 18.53 | 17.91 | 12.76 | 8.85 | 12.87 | |
Return on Capital Employed (%) | 24.78 | 23.41 | 18.54 | 12.25 | 18.17 | |
Return on Assets (%) | 13.97 | 14.30 | 10.29 | 6.62 | 10.10 | |
Total Debt/Equity (X) | 0.12 | 0.03 | 0.00 | 0.12 | 0.07 | |
Asset Turnover Ratio (%) | 0.67 | 0.70 | 0.68 | 0.62 | 0.65 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 1.91 | 3.22 | 3.11 | 2.23 | 2.40 | |
Quick Ratio (X) | 1.38 | 2.49 | 2.42 | 1.68 | 1.78 | |
Inventory Turnover Ratio (X) | 0.88 | 0.93 | 0.99 | 1.10 | 1.30 | |
Dividend Payout Ratio (NP) (%) | 12.45 | 15.31 | 19.05 | 25.54 | 18.96 | |
Dividend Payout Ratio (CP) (%) | 10.42 | 12.50 | 14.08 | 17.00 | 13.72 | |
Earnings Retention Ratio (%) | 87.55 | 84.69 | 80.95 | 74.46 | 81.04 | |
Cash Earnings Retention Ratio (%) | 89.58 | 87.50 | 85.92 | 83.00 | 86.28 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 97,822.47 | 102,161.00 | 76,348.99 | 71,782.46 | 74,673.98 | |
EV/Net Operating Revenue (X) | 4.23 | 5.24 | 4.50 | 4.98 | 5.59 | |
EV/EBITDA (X) | 11.67 | 15.05 | 15.89 | 23.34 | 18.96 | |
MarketCap/Net Operating Revenue (X) | 4.13 | 5.27 | 4.54 | 4.97 | 5.63 | |
Retention Ratios (%) | 87.54 | 84.68 | 80.94 | 74.45 | 81.03 | |
Price/BV (X) | 3.31 | 4.24 | 3.76 | 3.91 | 4.42 | |
Price/Net Operating Revenue | 4.13 | 5.27 | 4.54 | 4.97 | 5.63 | |
Earnings Yield | 0.06 | 0.04 | 0.03 | 0.02 | 0.03 |
17.09.2025
15.09.2025
11.09.2025
28.08.2025
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
23.07.2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs 1,418 crore, revenue up 11%
12.05.2025
Dr Reddys Labs Standalone March 2025 Net Sales at Rs 5,562.90 crore, up 8.97% Y-o-Y
12.05.2025
Dr Reddys Labs Consolidated March 2025 Net Sales at Rs 8,528.40 crore, up 19.89% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz